Co-led Enodia Therapeutics' €20.7M seed round with Pfizer Ventures and Bpifrance for a targeted protein-degradation platform.
Enodia Therapeutics is a biotechnology company developing small-molecule therapies that selectively degrade disease-driving proteins at the point of synthesis, focusing on immuno-inflammatory disorders
Enodia Therapeutics is a biotechnology company developing small-molecule therapies that selectively degrade disease-driving proteins at the point of synthesis, focusing on immuno-inflammatory disorders.